Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Jp1366 20mg 1capsule

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05247112Recruiting

Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea

NCT05194046Phase 1CompletedPrimary

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

Showing all 2 trials

Research Network

Common Treatments

  • Jp1366 20mg 1capsule1
  • Amoxicillin1
  • Clarithromycin1

Active Sponsors

  • Seoul National University Bundang Hospital1
  • Onconic Therapeutics Inc.1

Top Investigators

Related Conditions

  • Helicobacter Pylori Infection Susceptibility To1
  • Helicobacter Pylori Infection1
  • Helicobacter Pylori 23s Rrna Clarithromycin Resistance Mutation1

Activity Timeline